4.4 Article

Mifepristone regulates Tregs function mediated by dendritic cells through suppressing the expression of TGF-β

Journal

IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
Volume 43, Issue 1, Pages 85-93

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/08923973.2020.1867998

Keywords

Mifepristone; dendritic cells; Tregs; IDO; TGF-beta; immunomodulatory

Funding

  1. National Natural Science Foundation of China [81270730]
  2. Natural Science Foundation of Zhejiang Province, China [LY16H040005]

Ask authors/readers for more resources

The study found that mifepristone can promote the expression of CD80, CD86, and ICAM-1 in dendritic cells, while causing a significant decrease in the expression levels of FOXP3 and IL-10 in regulatory T cells. Additionally, using inhibitors or supplements, it was confirmed that TGF-beta, but not IDO, could rescue the downregulation of FOXP3 and IL-10 in Tregs co-cultured with mifepristone-treated DCs.
Background Previous studies have demonstrated that mifepristone in the daily low-dose affects the function of endometrium. These researches also implied an alteration of endometrium immune balance, which might be involved in regulating endometrial function. However, the detailed mechanisms remain to be further explored. Methods In this study, the expressions of CD80, CD86, and ICAM-1 in dendritic cells (DCs), which were stimulated with different concentrations of mifepristone (20, 65, and 200 nM), were detected by FACS. After that, we further evaluated the expression of Forkhead box P3 (FOXP3) and IL-10 in Tregs, which co-cultured with mifepristone treated DCs. In mechanism, we compared the indoleamine 2,3-dioxygenase (IDO) and TGF-beta expression with enzyme-linked immunosorbent assay (ELISA). Results The results indicated that mifepristone promoted the expressions of CD80, CD86, and ICAM-1 in a dosage dependent manner. Reversely, FOXP3 and IL-10 expression levels in Tregs co-cultured with mifepristone-treated DCs were significantly decreased compared with those co-cultured with nontreated DC. Furthermore, a significant reduce in IDO and TGF-beta expression was observed in DCs treated with mifepristone. By using the IDO inhibitor (1-methyl tryptophan, 1-MT) or TGF-b supplement, we confirmed that TGF-beta, but not IDO could rescue the downregulation of FOXP3 and IL-10 in Tregs co-cultured with mifepristone treated DCs. All of these results suggest that mifepristone may regulate DC function by decreasing TGF-beta expression, which further results in the downregulations of FOXP3 and IL-10 in Tregs. Conclusion Therefore, our research provides a theoretical basis for a potentially clinical application of mifepristone as a novel contraceptive.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available